Overview

A Study to Access the Safety & Efficacy Treatment in Rheumatoid Arthritis Patients naïve to DMARD Treatment (EXPAND)

Status:
Not yet recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks expended daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).

Phase:

Phase 2

Details

Lead Sponsor:

SynAct Pharma Aps

Collaborator:

NBCD A/S